龍韻股份(603729.SH):上半年預虧1200萬元-1650萬元
格隆匯7月14日丨龍韻股份(603729.SH)公佈,公司預計2022年半年度實現歸屬於上市公司股東的淨利潤為-1200萬元到-1650萬元;公司預計2022年半年度歸屬於上市公司股東扣除非經常性損益的淨利潤為-1240萬元到-1690萬元。
報吿期內,受上海新冠疫情影響,公司的生產經營至6月初才開始逐步恢復正常秩序,公司市場開拓受阻,部分客户削減了廣吿投放量並壓縮銷售訂單的毛利空間,使公司二季度銷售量及毛利率同比均有下降。同時,為了滿足未來戰略發展的需要,公司進一步儲備了行業優秀人才,運營費用同比有所增加。綜上,預計報吿期內將出現虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.